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Abstract: As platforms for therapeutic agents, monoclonal antibodies (MAbs) have already 
been approved, and several MAbs have demonstrated clinical effectiveness in a variety of 
malignancies. However, several issues have also been emerging in antibody therapy, such as 
high cost and insufﬁ  cient drug action. Recently, to improve MAb activity in humans, effector 
functions have been subjects of focus, especially antibody-dependent cell-mediated cytotoxicity 
(ADCC) and complement-dependent cytotoxicity (CDC). Extensive efforts have been made to 
enhance these effector functions of MAbs, and successful approaches have been reported by us 
and others, wherein the binding activity of MAbs to FcγRIIIa or C1q is increased by introduc-
ing amino acid mutations into heavy chain constant regions or through glyco-modiﬁ  cation of 
Fc-linked oligosaccharides. In addition, one of the next approaches to optimizing therapeutic 
antibodies would be to combine multiple enhancing modiﬁ  cations into a single antibody platform 
to overcome the diverse mechanisms of clinical resistance of tumor cells. For this aim, we have 
recently developed a successful combination composed of ADCC-enhancing modiﬁ  cation by 
the fucose depletion from Fc-linked oligosaccharides and CDC-enhancing modiﬁ  cation by IgG1 
and IgG3 isotype shufﬂ  ing in heavy chains, which could be of great value for the development 
of third-generation antibody therapeutics.
Keywords: ADCC, CDC, effector functions, Fc oligosaccharides, IgG isotypes, 
nonfucosylated IgG
Introduction: Current status of therapeutic 
antibodies
Since the late 1990s, more than 20 monoclonal antibodies (MAbs) have been approved 
as therapeutic agents, and MAbs are emerging as a major new class of drugs that confer 
great beneﬁ  ts to patients. In fact, therapeutic antibodies have demonstrated improve-
ments in overall survival and time to disease progression in a variety of malignancies, 
such as breast, colon, and hematological cancers.1–4 Recently, adding to antigen binding 
and speciﬁ  city, “effector functions” have come under increasing focus as a cause of drug 
action by therapeutic MAbs in humans. In particular, Fc gamma receptor (FcγR) IIIa-
dependent effector functions may be one of the major critical mechanisms responsible 
for the clinical efﬁ  cacy of therapeutic MAbs; this is supported by genetic analysis of 
working polymorphisms of the receptor in patients.5–9 FcγRIIIa, a member of the leukocyte 
receptor family FcγRs, is known to be a major triggering receptor of ADCC in natural 
killer (NK) cells. Several therapeutic MAbs are capable of ADCC, such as anti-CD20 
rituximab (Rituxan®), anti-Her2 trastuzumab (Herceptin®), anti-tumor necrosis factor-α 
(anti-TNF-α) inﬂ  iximab (Remicade®), and anti-RhD.5,6,9–14  Complement-dependent cyto-
toxicity (CDC), another effector function of antibody, is also considered a possible 
anti-tumor mechanism of rituximab and alemtuzumab (Campath-1H).15,16 Furthermore, 
most therapeutic antibodies that have been licensed and developed as medical agents are 
of the human IgG1 isotype, which can induce strong ADCC and CDC when compared 
with the other heavy chain isotypes of the human antibody. These effector functions are Drug Design, Development and Therapy 2009:3 8
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activated through the interactions of the Fc with either FcγRs 
or complements, and the interactions are affected by N-linked 
biantennary complex-type oligosaccharides attached to the anti-
body Fc region, which is heavily fucosylated in human IgG1. 
In addition to their multifunctional activities, therapeutic MAbs 
of human IgG1 isotype have long-term stability in blood via 
a unique neonatal Fc receptor (FcRn) mechanism, which has 
never been seen in small molecular drugs.17,18 Thus, the MAb 
platform is very suitable for developing medicines based on 
molecular targeting. However, we have also realized a short-
coming of the current generation of therapeutic antibodies, as 
exempliﬁ  ed by the insufﬁ  cient results of numerous clinical 
trials, especially in antibodies recognizing surface tumor anti-
gens, and by an economically intolerable cost with multiple 
high-dose administration treatment even in the case of effective 
therapeutic antibodies.19–22 It is time to design next-generation 
therapeutic antibodies that can overcome these issues.
Basic structure and physiological 
mechanism of therapeutic 
antibodies
Although five classes of immunoglobulin (IgM, IgD, 
IgG, IgA, and IgE) and four IgG subclasses (IgG1, IgG2, 
IgG3, and IgG4) are present in humans, IgG1 is primarily 
employed as a therapeutic agent due to its long half-life in 
blood (approximately 21 days) and due to its advantage 
in effector functions compared to those of the other Ig 
classes and subclasses.23 The MAbs of the human IgG1 
isotype has a basic structure of 150 kDa consisting of two 
immunoglobulin light chains and two immunoglobulin 
heavy chains in covalent and noncovalent association, 
resulting in the formation of three independent protein 
moieties – two Fab regions and one Fc region – which are 
connected through a ﬂ  exible linker designated as the hinge 
region (Figure 1). Fab regions in an antibody molecule are 
of identical structure, wherein each expresses a speciﬁ  c 
antigen-binding site, and the Fc region expresses interac-
tion sites for ligands which can induce effector functions, 
including three structurally homologous cellular Fc receptor 
types (FcγRI, FcγRII, FcγRIII), the C1q component of the 
complement, and the FcRn.24,25 The physiological activities 
of therapeutic antibodies are mediated by two independent 
natural immunoglobulin mechanisms: the efﬁ  cacy of thera-
peutic antibodies results from its speciﬁ  c and bivalent bind-
ing to the target antigen (eg, blockade or neutralization of 
target antigen or induction of apoptosis) and from effector 
functions that are activated only by the formation of immune 
complexes of the Fc and the effector ligands named above. 
Heavy chains are covalently paired by disulﬁ  de bonds in 
hinge regions, and the Fc region contains the CH2 domains 
and noncovalently paired CH3 domains (Figure 1). In the 
CH2 domains, an oligosaccharide is covalently attached to 
the both domains at asparagine 297 (Asn-297). The major 
interaction sites of the Fc to the effector ligands are in the 
hinge and CH2 regions, and the binding is known to depend 
on the glycoform of the oligosaccharides attached to the 
CH2 domains.23,26 The effector mechanisms mediated via 
FcγRI, FcγRII, FcγRIII, and C1q are severely compromised 
or abrogated in aglycosylated or deglycosylated forms of 
IgG1.25,27–29 In human IgG1, the Fc-linked oligosaccharide is 
of the biantennary complex type (Figure 2) and is composed 
of a mannosyl-chitobiose core structure in the presence or 
absence of a core fucose, a bisecting N-acetylglucosamine 
(GlcNAc), and terminal galactose and sialic acid. This 
structure gives rise to heterogeneity with a mixture of 30 
or more glycoforms.30–33 In general, the oligosaccharides 
of glycoprotein are attached to the molecular surface and 
thought to cover the protein portion just like a cachet. 
However, crystal structure analysis has revealed that the 
Fc-linked oligosaccharides of human IgG1 antibody are 
integral to the Fc region and inﬂ  uence the conformation of 
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Figure 1 Structure of human IgG1 antibody. The Mabs of human IgG1 isotype 
consists of two immunoglobulin light chains and two immunoglobulin heavy chains. 
Heavy chains are covalently paired by disulﬁ  de bonds in hinge regions, and each heavy 
chain is connected to a light chain by a disulﬁ  de bond between CH1 and CL. A pair 
of VH and VL in Fab regions makes an antigen binding site. In the CH2 domains of Fc 
regions, an oligosaccharide is covalently attached to the both domains at asparagine 
297 (Asn-297).Drug Design, Development and Therapy 2009:3 9
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the Fc via the multiple noncovalent interactions with the 
CH2 domains.34–36 Therefore, the oligosaccharide inﬂ  uences 
the Fc structure, and there are suitable oligosaccharide 
structures among the natural heterogeneity of the Fc-linked 
oligosaccharides for the binding between Fc and effector 
ligands. For example, human IgG1 antibodies bearing 
the Fc-linked oligosaccharides lacking core fucose show 
improved binding to FcγRIIIa and much enhanced ADCC 
compared to fucosylated ones.37
Importance of ADCC on the clinical 
efﬁ  cacy of therapeutic antibodies
There is a substantial discrepancy between the potency 
of therapeutic antibodies in vitro and in vivo in terms of 
the required doses, especially in the anticancer therapies. 
Cancer patients treated with therapeutic antibodies typi-
cally need to receive weekly doses of several hundred mil-
ligrams over several months to maintain an effective serum 
concentration of over 10 μg/ml.38–40 On the other hand, the 
maximal in vitro cellular cytotoxicity by ADCC of these 
therapeutic antibodies can be achieved at an antibody con-
centration of less than 10 ng/mL, which is several orders 
of magnitude below the targeted serum concentrations in 
vivo.41,42 This discrepancy – that is, the low in vivo efﬁ  -
cacy of therapeutic antibodies in contrast to the high in 
vitro cytotoxicity is primarily due to competition between 
human serum IgG and therapeutic antibodies for binding 
to FcγR on effector cells; namely, endogenous human 
serum IgG strongly inhibits ADCC induced by therapeu-
tic antibodies.43–46 Although the importance of antibody 
effector functions of ADCC on the clinical efﬁ  cacy of 
therapeutic antibodies has long been a matter of debate, 
recent clinical evidence based on genetic analysis of FcγR 
polymorphisms in cancer patients treated with anti-CD20 
rituximab and anti-HER2 trastuzumab therapies has sug-
gested the importance of ADCC.5,6,9–11 The superior clinical 
response of patients carrying the high-afﬁ  nity FcγRIIIa 
allotype (FcγRIIIa-158Val) for anti-CD20 rituximab has 
been demonstrated, in contrast to that of patients carrying 
the low-afﬁ  nity allotype (FcγRIIIa-158Phe).5,6,9,10 Breast 
cancer patients who responded to anti-HER2 trastuzumab 
with complete or partial remission have been found to 
have a higher capability to mediate in vitro ADCC by 
trastuzumab than nonresponders.11 A signiﬁ  cant correlation 
has also been reported between the clinical responses of 
the therapies and the polymorphisms of low-afﬁ  nity FcγR 
in some diseases, such as rituximab-treated patients with 
systemic lupus erythematosus (SLE) and Waldenstrom’s 
macroglobulinemia, Crohn’s disease patients treated with 
anti-TNF-α inﬂ  iximab, and pregnant women with fetal 
hemolytic disease treated with anti-RhD.9,12–14 Thus, the 
importance of ADCC for the clinical efﬁ  cacy of thera-
peutic antibodies is now widely recognized, and ADCC 
enhancement technology is expected to play a key role in 
the development of next-generation therapeutic antibodies 
with improved clinical efﬁ  cacy.
ADCC-enhancing technology
Artiﬁ  cial amino acid modiﬁ  cations in the Fc
The effector functions of an antibody can be manipulated 
by engineering amino acid sequences of the constant 
regions. In particular, facilitating FcγRIIIa binding 
by mutated antibody sequences may be of therapeutic 
value. Thus, amino acid alterations in the Fc that possess 
improved FcγRIIIa binding and resultant ADCC-enhancing 
capacity have been extensively studied, mainly by biotech 
companies, using random or rational designing approaches 
with high-throughput protein expression systems. A group 
at Genentech has discovered variant Fcs with enhanced 
ADCC-inducing capacity having up to three mutations, 
based on a comprehensive alanine scanning method on 
the accessible surface of the Fc.47 The Xencor group has 
employed a computational design algorithm and found a set 
of Fc variants with extremely strong FcgRIIIa binding (up 
to 100-fold enhancement in KD), which showed a strong 
cytotoxic activity in cynomolgus monkeys.48 The Macro-
genics group has also described Fc mutants with enhanced 
ADCC by using a unique yeast display system.49,50
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Figure 2 Fc-Linked oligosaccharides of antibodies. A conserved oligosaccharide core, linked to the Asn-297, is composed of a mannosyl-chitobiose core structure in the 
presence or absence of a core fucose (Fuc), a bisecting N-acetylglucosamine (GlcNAc) and terminal galactose (Gal) and sialic acid; this structure gives rise to heterogeneity 
with a mixture of 30 or more glycoforms.
Abbreviations: Man, mannose monosaccharide residue.Drug Design, Development and Therapy 2009:3 10
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Removal of fucose from Fc-linked 
oligosaccharides
It is widely recognized that the core fucose of Fc-linked 
oligosaccharides greatly affects the ADCC of therapeutic 
antibodies and the removal of the fucose markedly enhances 
the ADCC via improved FcγRIIIa binding without altering 
antigen binding or CDC. ADCC enhancement by fucose 
removal is now considered a very important technique 
for the development of therapeutic antibodies mediat-
ing ADCC.21,37,41,42,45,51–63 The MAbs of IgG1 bearing the 
biantennary-complex type of Fc-linked oligosaccharides 
lacking core fucosylation exerts the strongest ADCC in 
a comparison of glycoforms.51 In human IgG, Fc-linked 
oligosaccharides lacking core fucose exist as portions of 
naturally occurring heterogeneities, and therefore there is 
little concern regarding its intrinsic immunogenicity.31,32 
Importantly, the enhancement of ADCC by the core fucose 
removal is thought to leach the saturated level, according 
to a study wherein no signiﬁ  cant difference in ADCC was 
detected between the ADCC-enhanced IgG1 by either 
the core fucose removal or amino acid mutations S239D/
S298A/I332E, which have higher FcγRIIIa binding afﬁ  n-
ity.60 Moreover, no additive effect is shown on the B-cell 
depletion activity of anti-CD20 IgG1 rituximab in human 
blood by the combination of these techniques, although 
an additive increase in FcγRIIIa binding is observed in a 
BIAcore biosensor analysis. Thus, the enhanced FcγRIIIa 
binding of nonfucosylated antibodies appears to be sufﬁ  cient 
to maximize the ADCC of therapeutic antibodies without 
introducing artiﬁ  cial amino acid mutations. Furthermore, 
the nonfucosylated antibodies have achieved high effector 
activity at low doses, against tumor cells expressing low 
levels of antigen, or even in NK cells harboring the low-
afﬁ  nity FcγRIIIa allotype (FcγRIIIa-158Phe).41,53 Strong 
ADCC enhancement of the nonfucosylated therapeutic 
antibodies has also been demonstrated in the analysis using 
NK cells derived from breast cancer patients.54 These results 
showing ADCC enhancement are well reﬂ  ected by in vivo 
analysis. The superior in vivo efﬁ  cacy of nonfucosylated 
antibodies has also been demonstrated in the mouse model 
of engrafted human peripheral blood mononuclear cells 
(PBMC), and nonfucosylated antibodies have shown 
improved B-cell depletion activity in human blood analysis 
in vitro despite the strong inhibitory effects of human 
serum IgG molecules.21,42,45,51 In spite of the great beneﬁ  ts 
of nonfucosylated antibodies, currently licensed therapeutic 
antibodies are composed of a mixture of fucosylated and 
nonfucosylated immunoglobulin molecules (over 90% of the 
Fc-linked oligosaccharides are fucosylated) and therefore 
unfortunately fail to achieve optimized ADCC due to the 
competition between the two forms for the antigens on the 
target cells.21,45,51 This is the case because the construction of 
a robust process for the production of therapeutic antibodies 
lacking core fucosylation has proven to be a challenge.64,65 
However, the manufacture of recombinant therapeutic 
antibodies fully lacking core fucosylation with a ﬁ  xed quality 
has been achieved through gene engineering of the fucosyl-
ation pathway in the cells for antibody production.52,66–68 
The application of nonfucosylated antibodies is expected 
to be among the most powerful and elegant approaches to 
improving the efﬁ  cacy of therapeutic antibodies, and the 
use of cells with α-1,6-fucosyltransferase gene (FUT8) 
knockout is one of the most successful approaches for the 
manufacture of nonfucosylated antibodies (Potelligent 
technology). Nonfucosylated products manufactured using 
this approach have already been entered into multiple clini-
cal trials.
CDC as an effector function
of therapeutic MAbs
CDC is a cytolytic cascade mediated by a series of comple-
ment proteins abundantly present in serum. It is triggered 
by the binding of C1q to the constant region of cell-bound 
antibody molecules (Figure 3). For the induction of strong 
CDC activity, various biological and structural features 
of antigen molecules are required, such as relatively high 
expression, the presence of small or folded extracellular 
portions, or epitopes that retarget antigens into lipid rafts 
in the case of anti-CD20 MAbs.69,70 In addition, CDC is 
negatively regulated by complement-regulatory proteins 
(CRPs: CD46, CD55, and CD59) expressing on the cell 
surface.71,72 The relationship between complement activa-
tion and therapeutic activity is also suggested in several 
reports. For example, Kennedy and colleagues have 
reported rapid complement consumption after rituximab 
administration, and Treon and colleagues have reported 
upregulation of CRPs in returning tumor cells after ritux-
imab treatment.73,74
CDC-enhancing technologies
The binding of the C1q component to the Fc, the initial 
step of the complement cascade, affects the intensity of the 
following complement activation, and several approaches 
have succeeded in enhancing CDC by facilitating the 
binding of the antibody constant region to C1q. As a result of 
engineered amino acid mutations inserted into either Fc or the Drug Design, Development and Therapy 2009:3 11
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hinge region, designed antibody constant regions possessing 
improved C1q binding have been achieved.75,76
Another example of CDC enhancement is the engineering 
of the heavy chain by shufﬂ  ing IgG1 and IgG3 sequences 
within a heavy chain constant region, as recently reported by 
our group; this is called Complegent technology (Figure 4).77 
Apart from amino acid and structural idiosyncrasies, the four 
isotypes of human IgG differ from each other in the potencies 
of effector functions and other activities.41,78–82 In general, the 
rank orders of potency are IgG1  IgG3  IgG4  IgG2 for 
ADCC and IgG3  IgG1  IgG2 . = . IgG4 for CDC.6,56,78–81 As 
a result of the comparison of a comprehensive set of structural 
shufﬂ  ing between IgG1 and IgG3, the mixed isotype heavy 
chain variant, wherein a part of the Fc portion of human 
IgG1 heavy chain is converted into the corresponding part 
of human IgG3 (Complegent), showed unexpectedly strong 
C1q binding and CDC that was even better than those of 
parental IgG1 and IgG3. ADCC of the Complegent antibody 
was unchanged from that of parent IgG1 antibody. Further-
more, an anti-CD20 antibody with Complegent-type constant 
regions have shown improved B-cell depletion in cynomol-
gus monkeys compared to anti-CD20 IgG1.77 As a result of 
single intravenous injection, signiﬁ  cant enhancement in the 
levels of B-cell depletion was observed for Complegent-
type antibody, which was manifested in a signiﬁ  cant delay 
in time to recovery of B cells. This approach succeeded in 
enhancing CDC also in the therapeutic anti-CD52 antibody 
alemuzumab, and thus may be applicable to a wide range of 
target molecules.
Enhancement of multiple 
anti-tumor functions:   The next 
target of antibody optimization?
As discussed above, antibody effector functions can be 
manipulated by engineering amino acid sequences of the 
constant regions. Amino acid alterations in the Fc that possess 
improved FcγRIIIa binding and resultant ADCC-enhancing 
capacity have been extensively studied and successfully 
obtained by mutational or computational analyses on the Fc: 
FcγRIIIa contact site or by direct evolutional methods using 
a comprehensive display library.47,48,50,83 Similarly, binding 
to C1q or the neonatal Fc receptor, which is involved in IgG 
clearance, can also be improved by introducing amino acid 
mutations into the Fc or the hinge.75,76,84,85 Typically, these 
variant Fcs require at least 2 to 5 amino acid alterations from 
unmutated wild-type sequences.
One of the next directions for the optimization of 
therapeutic antibodies would be to combine multiple 
enhancing modiﬁ  cations into a single antibody platform. In 
theory, different Fc modiﬁ  cations can be “piled up” to create 
a variant sequence having accumulated amino acid mutations 
that possess multiple enhanced functions. Stavenhagen 
and colleagues have reported a successful example of an 
engineered Fc sequence having ﬁ  ve amino acid mutations and 
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Figure 3 Schematic diagram of CDC. CDC is a cytolytic cascade mediated by a series of complement proteins abundantly present in serum. It is triggered by the binding of 
C1q, a subunit of C1, to the constant region of cell-bound antibody molecules. Finally, activated complements form menbrane-attack complex, perforating membrane.Drug Design, Development and Therapy 2009:3 12
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possessing enhanced binding capacity to both FcγRIIa and 
FcγRIIIa.50 Nevertheless, the effect of combining multiple 
sets of amino acid alterations would be difﬁ  cult to predict, 
probably because the conformational change of overall 
antibody molecules could lead to unexpected changes in 
some biological activities. Actually, artiﬁ  cial Fc mutations 
have often been reported to induce unpredictable functional 
impairments; for example, a reduction in FcγRIIIa-binding 
activity is often seen for the Fc mutations that improve anti-
body binding to C1q, FcγRII, or FcRn.47,75,85 Notably, these 
unpredictable phenomena did occur even though the FcγRIIIa 
contact sites of IgG did not always overlap with other contact 
sites, especially for those of FcRn (located in the CH2:CH3 
cleft), which seem to be far apart from the FcγRIIIa binding 
sites (located between the two lower hinges.35,86,87
Despite such technical limitations, many companies have 
made extensive progress in developing the next-generation 
anti-CD20 antibodies since the successful launch of 
rituximab. Now multiple new anti-CD20 antibodies with 
diverse effector functions are beginning to enter clinical 
trials (Table 1).
Many of the new anti-CD20 antibodies are designed to 
improve the ADCC of rituximab. Some of them might be 
attributable to the inherent properties of parent antibodies 
different from those of rituximab (clone 2B8). Interestingly, 
some antibodies possess engineered constant regions with 
increased ADCC-inducing capacity, either by mutat-
ing amino acid sequences of   the Fc (AME-133) or by 
engineering the glycoform of the Fc-linked oligosaccharides 
(GA101).
AccretaMAb platform: A universal 
platform technology for the 
next generation of therapeutic 
antibodies with enhanced ADCC 
and CDC
An important feature of Potelligent technology is that it can be 
applied to a broad spectrum of antibody backbone structures. 
This ADCC-enhancing effect of defucosylation was initially 
found for human IgG1 background, and was then expanded 
to include various types of immunoglobulins (other human 
IgG subclasses or murine IgG2) and antibody-like engineered 
molecules (Fc fusion proteins).37,55–57,59,92 In every case exam-
ined, fucose removal did not seem to inﬂ  uence any biological 
activities other than FcγRIIIa-related functions. Although 
fucose removal from antibody oligosaccharides is associated 
with a signiﬁ  cant thermodynamic change in the FcγRIIIa-
binding state of IgG1,62 it does not signiﬁ  cantly inﬂ  uence 
the overall IgG1 conformation except for a small change in 
the hydration mode around the fucose residue as revealed 
by crystal structure and NMR analyses.63 It is likely that the 
minimal conformational change allows this phenomenon to 
be easily applied to a wide range of antibody species.
More recently, we have shown that fucose removal 
from Complegent antibodies (IgG1/IgG3 chimeric isotype 
antibodies), in what we call the AccretaMAb platform, 
results in the full retention of potent ADCC and CDC, to 
levels that are comparable to those seen for Potelligent 
Domains of human IgG1
CH1 Hinge CH2 CH3
IgG1
IgG3
Complegent
Domains of human IgG3
Heavy chain constant domains
Fc
Figure 4 Scheme of the mixed isotype heavy chain. In the mixed isotype heavy chain 
variant, a part of the Fc portion of human IgG1 heavy chain is converted into the 
corresponding part of human IgG3 (Complegent).
Table 1 Effector functions of selected next-generation anti-CD20 MAbs
Antibody Developer Type Parent MAb Effector functions in comparison
with rituximab
Reference
Ofatumumab GSK/Genmab IgG1 2F2 Potent CDC 88
Ocrelizumab Genentech IgG1 2H7 Potent ADCC and decreased CDC 89
Veltuzumab Immunomedics IgG1 2B8 Comparable to rituximab 90
AME-133 AME Mutated IgG1 Synthetic Potent ADCC 83
GA101 Roche/GlycArt Glycoengineered IgG1 B1 Potent ADCC/direct apoptosis, no CDC 91Drug Design, Development and Therapy 2009:3 13
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or Complegent alone, respectively.77 The successful 
combination of ADCC- and CDC-enhancing modifica-
tions in the AccretaMAb platform is constituted by two 
essential structural factors: (i) IgG1/IgG3 mixed constant 
regions that enhance C1q binding and CDC activity, and (ii) 
nonfucosylated oligosaccharides linked to the Fc of the mixed 
variant constant regions that maximize its ADCC.
As for the structural basis of AccretaMAb, how the 
IgG1/IgG3 chimeric isotype sequence greatly enhances CDC 
activity remains elusive. Interestingly, in addition to the hinge 
derived from IgG1 and the CH2 from IgG3, the other con-
stant domains (the CH1 from IgG1 and the CH3 from IgG3) 
are also required for its optimized CDC activity. The CH1 
and the CH3 domains are not considered direct contact sites 
between IgG:C1q, as revealed by a comprehensive structural 
shufﬂ  ing analysis between IgG1 and IgG3.77 Thus it appears 
likely that the speciﬁ  c combinations of multiple IgG domains 
of different subclasses render the overall variant antibody 
conformation capable of binding C1q with unexpectedly 
strong afﬁ  nity. Importantly, the FcγRIIIa binding and the 
ADCC of this novel chimeric constant region are as strong as 
those of IgG1, and can be further maximized by the removal 
of fucose from Asn297-linked oligosaccharides.77
Clinical implication of engineered 
antibodies with multiple-enhanced 
functions
It has been suggested that tumor cells avoid attack from 
therapeutic antibodies by using various mechanisms, which 
might lead to insufﬁ  cient efﬁ  cacy in the clinic (Table 2).
Thus, in order to overcome the diverse mechanisms 
underlying clinical resistance by tumor cells, the enhancement 
of multiple functions of therapeutic antibodies might be a 
promising approach. Regarding AccretaMAb, for example, 
the dual enhancement of effector functions (ADCC and CDC) 
is expected to bring some additional advantages; these two 
functions might act complementarily. For instance, tumor 
cells that are highly resistant to attack by complementary 
regulatory proteins would be destroyed more effectively by 
potent ADCC due to defucosylated Fc-linked oligosaccha-
rides. Conversely, in circumstances where the accessibility 
of ADCC effector cells is severely limited by tight solid 
tumor tissues, the potent CDC of AccretaMAb, which does 
not require cellular factors, would be a powerful weapon for 
eliminating tumor cells.
Furthermore, the increased complement ﬁ  xating and 
enhanced ADCC activities might have a synergistic effect 
through an interaction between complement opsonized on 
the target cells and complement receptors (eg, CR3) present 
on effector cells, which would increase ADCC of antibodies. 
However, the clinical importance of this mechanism is far 
less validated and remains to be elucidated.93
One of the potential issues in future therapy with arti-
ﬁ  cially engineered antibodies is immunogenicity; namely, 
the use of mutated sequences may increase the risk of 
newly generated non-self peptides that bind to MHC class II 
molecules, especially for those having a higher number 
of accumulated amino acid alterations. Interestingly, the 
AccretaMAb platform is fully composed of natural structural 
components: IgG1 and IgG3 sequences and nonfucosylated 
N-linked oligosaccharides (constitutes ∼10% of human serum 
IgG oligosaccharides).94 Future clinical trials of AccretaMAb 
will also conﬁ  rm the hypothesis that the variant constant 
regions consisting of fully natural components would render 
the antibodies potentially less immunogenic compared to 
artiﬁ  cial mutation approaches.
Perspectives
After a number of successes and failures in the lab, engi-
neered antibodies with optimized effector functions now 
Table 2 Proposed mechanisms of resistance by tumor cells to antibody therapy
(i) Tumor factors
 ⋅  Poor penetration of effector cells of ADCC into solid tumor tissues
 ⋅  Complement-regulatory proteins (CD46, CD55, and CD59) on the tumor cells
 ⋅  Soluble antigens
 ⋅  Altered signaling (eg, bcl-2 elevation in rituximab therapy)
(ii) Host factors
 ⋅  Heterogeneity in ADCC according to FcγRIIIa functional polymorphism
 ⋅  Inactivation of effector cells in patients (eg, downregulation of ζ chain, NKG2D, NKp30, NKp44, or NKp46 in NK cells)
(iii) Therapy factors
 ⋅  Suppression of effector cells by chemotherapyDrug Design, Development and Therapy 2009:3 14
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appear to be coming of age as pharmaceuticals. Now many 
believe that enhancing ADCC is one of the most promising 
ways to improve the clinical efﬁ  cacy of already-approved 
antibodies, and this concept is actively being examined 
in the clinic, especially in the field of hematological 
malignancy treatment. However, considering the limited 
efﬁ  cacy of therapies with already-approved antibodies – 
especially for solid tumors (eg, cetuximab, bevacizumab, 
and trastuzumab), in which only small percentages of 
patients can achieve a partial response and most responders 
will relapse when given as monotherapy – there remains 
a critical need to improve the anti-tumor mechanisms of 
therapeutic antibodies.
What will go beyond “enhancing ADCC alone”? A major 
obstacle to predicting the critical mechanism that actually 
functions in patients is the lack of an appropriate animal 
model. The immune systems of animals are far different from 
that in humans in terms of effector functions; for example, 
the most widely used murine tumor models do not have the 
capacity to induce ADCC or CDC.95 Although several efforts 
to evaluate ADCC- or CDC-enhancing antibodies in vivo 
have been made to circumvent this limitation, such as the 
introduction of human effector cells into mice or establishing 
human FcγRIII transgenic mice, the actual potency of engi-
neered antibodies in the clinic is still difﬁ  cult to foresee 
by using these models with limited clinical predictability. 
Monkey models would be effective tools to evaluate the in 
vivo activity of ADCC and/or CDC-based antibodies,48,77,96 
however, the use of this model is limited for antibodies 
targeting leukocyte antigens. Importantly, good anti-tumor 
activity seen in the early-stage clinical trials of ofatumumab 
may provide a clue to this unanswered question; enhancing 
complement activation may add to the therapeutic efﬁ  cacy of 
approved antibodies. We believe that the promising combina-
tion of the two clinically proven effector functions, namely 
ADCC and CDC, will be conﬁ  rmed in future clinical trials 
of AccretaMAb antibodies.42,50,88
It is obvious that the choice of target functions of an 
antibody to be enhanced should be determined carefully 
based on a biological and mechanistic understanding of the 
target tumors and antigens, since various cancer subtypes 
of different origins display diverse biological proﬁ  les 
and resultant mechanisms of clinical resistance. Yet the 
major issue of current antibody therapy remains insufﬁ  -
cient efﬁ  cacy. Therefore, the expanding technologies that 
enhance multiple anti-tumor mechanisms of therapeutic 
antibodies would be of great value for the development of 
third-generation antibody therapeutics as long as they are 
used in the right patients, with the right dosage and on the 
right schedule, and perhaps monitored with appropriate 
biomarkers.
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